| NSNCX | VSGIX | NSNCX / VSGIX | |
| Total Expense Ratio | 2.02 | 0.06 | 3,367% |
| Annual Report Gross Expense Ratio | 2.25 | 0.06 | 3,750% |
| Fund Existence | 17 years | 26 years | - |
| Gain YTD | 4.108 | 10.370 | 40% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 1000 | 5000000 | 0% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 535M | 39.7B | 1% |
| Annual Yield % from dividends | 0.00 | 0.55 | - |
| Returns for 1 year | 1.34 | 7.55 | 18% |
| Returns for 3 years | 41.82 | 56.66 | 74% |
| Returns for 5 years | -11.43 | 14.43 | -79% |
| Returns for 10 years | 76.34 | 155.43 | 49% |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| PHDG | 37.92 | 0.17 | +0.45% |
| Invesco S&P 500® Downside Hedged ETF | |||
| REAI | 18.93 | N/A | N/A |
| Intelligent Real Estate ETF | |||
| RSDE | 21.90 | -0.03 | -0.15% |
| FT Vest U.S. Eq Eql Wght Buffr ETF - Dec | |||
| REGL | 85.52 | -0.17 | -0.19% |
| ProShares S&P MidCap 400 Dividend Arst | |||
| PJP | 107.85 | -0.23 | -0.21% |
| Invesco Pharmaceuticals ETF | |||